Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MD
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.
▶︎
Panel Shares Thoughts on EV-302 Study: Response Rate, Toxicities, Progression, and More
▶︎
EV-302 Results and How They Compare to the JAVELIN Paradigm
▶︎
Targeting RAS in Pancreatic Cancer: Is the "Undruggable" Era Finally Over?
▶︎
Bladder Cancer and Immunotherapy with Dr. Arjun Balar
▶︎
Incredible Recovery: From Stage 5 Kidney Disease to Healthy Kidneys - Eric's Story
▶︎
EV/Pembro and New Treatment Options for Metastatic Bladder Cancer
▶︎
'CANCER OCCURRED near injection sites...': Bombshell testimony ‘EXPOSES’ COVID-19 vaccine injuries
▶︎
Kidney Cancer / Renal Cell Carcinoma: EXPLAINED
▶︎
SENIORS: 5 Foods That Help Fight Against Cancer & Repair The Body
▶︎
Dr. Guru Sonpavde Discusses AMBASSADOR, NIAGARA, CM901, and PRT3789 at ESMO 2024
▶︎
TKI/IO Comparison: Lenvatinib/Pembrolizumab vs Cabozantinib/Nivolumab vs Axitinib/Pembrolizumab
▶︎
'All of them took BOOSTERS': Witness’ explosive claim linking mRNA COVID vaccines to cancer relapse
▶︎
Pioneering Precision Medicine in Bladder Cancer
▶︎
This One Muscle Is Destroying Your Leg Circulation (And You Don't Even Know It)
▶︎
Surgery or Radiotherapy for Prostate Cancer? Here's What the Evidence Shows
▶︎
KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer
▶︎
Multidisciplinary Realities: Tumor Board vs Tuesday Afternoon
▶︎
The Latest in Immunotherapy to Treat Cancer
▶︎
Repatha vs Statins: Which One Actually Prevents Heart Attacks?
▶︎